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RRM1 is the regulatory subunit of ribonucleotide reductase. It is cru-
cial for DNA synthesis and damage repair. In addition, high levels of 
RRM1 are associated with G2 cell cycle arrest and increased apoptosis 
in vitro. To assess its prognostic utility on lung cancer outcome in 
patients with complete surgical resection of NSCLC, we analyzed its 
level of expression by real-time quantitative RTPCR in prospectively 
collected fresh-frozen tumor specimens and independently in formalin-
ﬁxed and parafﬁn-embedded (FFPE) tumor specimens by quantitative 
in situ ﬂuorescence immunohistochemistry (AQUA). We found that 
RRM1 expression was directly correlated with survival; i.e., high levels 
of expression were prognostic of long survival. mRNA and protein 
expression levels of RRM1 were modestly but signiﬁcantly corre-
lated (JCO 22:1878, 2004; NEJM 356:800, 2007). Prior retrospective 
studies had suggested that patients with advanced stage NSCLC and 
high tumoral RRM1 levels that received gemcitabine-based double 
agent chemotherapy did worse than those with low RRM1 levels. This 
paradox has been explored through molecular biological studies in 
recent years. The results of these studies, which have been conducted 
in NSCLC (Cancer Res 64:3761, 2004; JCO 24:4731, 2006), colorectal 
cancer (Cancer Res 65:9510, 2005), and pancreatic cancer (Int J Cancer 
120:1355, 2007) by independent laboratories around the world have un-
equivocally demonstrated that RRM1 is the dominant molecular deter-
minant of gemcitabine efﬁcacy in vitro, in experimental animals, and in 
patients. Thus RRM1 expression in lung cancer patients is a prognostic 
marker; i.e., high levels are associated with good outcome independent 
of therapy; and a predictive marker; i.e., high levels are associated with 
resistance to therapy that is gemcitabine-based. Prospective multi-in-
stitutional clinical trials have been initiated with the goal to utilize this 
knowledge for therapeutic decision making.
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Unlike some tumor types, the majority of the common solid tumors ap-
pear not to be driven by single dominant targetable pathways. Instead, 
diseases such as lung cancer are likely to be much more complex and 
heterogeneous, with many distinct and overlapping subsets of tumors 
within the class, each of which will demand an in depth analysis to 
deﬁne the optimal therapeutic approach. These groups are starting to be 
deﬁned by multiple technologies, and the simplest example is the small 
subset of patients with tumors expressing mutant EGFR, who achieve 
substantial clinical beneﬁt from minimally toxic targeted therapy. Even 
for this small subset of patients with mutant epidermal growth factor 
receptors (EGFR), multiple resistance mechanisms have emerged re-
quiring different salvage strategies. There also appears to be a group of 
patients without EGFR mutations who experience clinically signiﬁcant 
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survival beneﬁt, and identiﬁcation of this subset would also have sig-
niﬁcant clinical beneﬁt. Toward this end, we have used matrix-assisted 
laser desorption/ionization time-of-ﬂight mass spectrometry (MALDI 
MS) as a rapid, affordable and simple strategy that can be applied to the 
analysis of complex biological samples such as serum, urine and tissue. 
Peaks in the mass spectrum correspond to ions formed from relatively 
abundant species in the sample, predominantly peptides and proteins. 
We have used MALDI MS to study unfractionated, pretreatment sera to 
identify NSCLC patients with improved survival after treatment with 
the EGFR TKIs geﬁtinib and erlotinib(1). Mass spectra, independently 
acquired at two institutions, gave highly concordant results, and were 
used to generate an algorithm predictive of time to progression and sur-
vival. This prediction algorithm was then validated in a blinded manner 
in two independent cohorts of NSCLC patients treated with EGFR 
TKIs. This classiﬁcation algorithm did not predict outcome in three 
independent cohorts of patients who did not receive treatment with 
EGFR TKIs. Thus, if upheld in prospective clinical trials, this simple, 
rapid, and inexpensive analysis of pre-treatment peripheral blood might 
be useful in selecting therapy for advanced non-small cell lung cancer 
patients.
1. Taguchi F, Solomon B, Gregorc V, et al. Mass Spectrometry to Classify NSCLC 
Patients for Clinical Outcome after Treatment with EGFR Tyrosine Kinase Inhibitors: A 
Multi-Cohort Cross Institutional Study. J Natl Cancer Inst 2007;In press.
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Non-small cell lung cancer (NSCLC) constitutes approximately 80% 
of all lung cancers, and tumor stage is the primary determinant of prog-
nosis for these patients (1). The term “early stage” has been commonly 
used to represent stage I and II patients. These are patients who have 
potentially curable disease by complete surgical resection. However, 
the overall prognosis of these early stage patients remains relatively 
poor with 5-year survival rates of 30-60% (2). Variation in survival 
largely reﬂects heterogeneity in the tumor biology, with some tumors 
having more aggressive growth and greater metastatic potential than 
others. While histology subtypes and grades demonstrate some impact 
on the prognosis of NSCLC patients, the overall differences are not 
sufﬁciently great to affect treatment decisions (3). An ability to identify 
molecular characteristics that can improve the classiﬁcation of patient 
prognosis additional to tumor stage would provide the rationale for ad-
juvant therapy to patients with the signiﬁcantly poorer prognosis. With 
recent trials showing that adjuvant chemotherapy signiﬁcantly improve 
the survival of stage II-IIIA patients, the development of molecular 
prognostic markers has assume some urgency. 
The ﬁrst evidence that a molecular aberration in lung cancer can be a 
prognostic marker was the KRAS oncogene. Slebos et al (4) reported 
that oncogenic KRAS mutations occurred in 30% of lung adenocar-
cinoma and its presence deﬁned a subgroup of patients with very 
poor prognosis. Since then, more than ﬁfty retrospective and mostly 
institutional-based studies were conducted to validate this report, but 
they provided contradicting results. A meta-analysis on 23 PCR-based 
studies (2632 patients) involving NSCLC patients and 11 studies (1170 
patients) involving only adenocarcinoma patients recorded RAS muta-
tion hazard ratios (HR) of 1.39 (95% conﬁdence interval 1.22 - 1.58; 
p=0.03) and 1.50 (95% CI 1.26-1.80; p=0.1), respectively (5). These 
results strongly suggest that RAS mutation is a poor prognostic marker 
in NSCLC patients. However, the only two studies that involved phase 
III randomized adjuvant clinical trial patients, the ECOG E4592 (6) 
and NCIC CTG JBR.10 (7) trials, failed to show a prognostic value for 
RAS mutation. 
Similar to RAS, abnormal p53 protein expression and p53 gene muta-
tions have been extensively investigated for their prognostic value in 
early stage resected NSCLC patients. Despite discrepancies among 
individual studies, results of two meta-analyses involving overlapping 
published data provided strong evidence that both abnormal p53 protein 
expression (positive immunohistochemistry) and p53 gene mutation are 
poor prognostic markers, and the impact appears greater in adenocar-
cinoma compared to squamous cell carcinoma (8, 9). Nevertheless, 
neither RAS and p53 mutation analyses nor p53 immunohistochemistry 
are routinely performed in clinical practice, as further evidence of their 
impact on patient selection for adjuvant chemotherapy is needed. 
Over the last two decades, there has been an exponential growth in our 
knowledge of the nature of human genome, genes that make up our 
chromosomes, molecular signaling pathways that regulate cellular pro-
cesses, and aberrations in the genetic and signaling networks in cancers 
and cancer cells. With completion of the human genome project, the 
identiﬁcation of all 30-50 thousand human genes is nearly complete. 
Microarray technologies were developed to facilitate the evaluation of 
this new genetic information at a genome-wide scale. The ﬁrst series 
of microarray studies in lung cancer demonstrated that gene expression 
proﬁling was able to distinguish different histological types of lung 
cancers (10, 11). These and other studies also reported that there are 
expression signatures that can identify patients with signiﬁcantly differ-
ent prognosis (12,13). However, it soon became apparent that the sets 
of prognostic signature genes from different studies showed minimal 
overlaps. Furthermore, analyses of a microarray dataset using differ-
ent statistical or computational algorithms could yield different sets of 
putatively prognostic gene signatures (14,15). The apparent discrepan-
cies between these studies were attributed putatively to variability in 
microarray platforms used, data processing, analytical algorithm and 
demographic differences in the patient cohorts studied. Nevertheless, 
these studies provided the important proof of principle that microar-
rays could yield biologically relevant information for deﬁning tumor 
characteristics beyond histology. While the initial prognostic signatures 
are composed of hundreds to thousands of gene probes, validation 
of these microarray results using the more quantitative assay called 
reverse transcription quantitative polymerase chain reaction (RT-qPCR) 
led to the identiﬁcation of smaller sets of prognostic gene classiﬁers, 
but further conﬁrmation of the latter in separate cohorts of patients was 
challenging (16,17). More recently, seemingly more rational approach-
es to identify prognostic gene classiﬁers based on patients’ extreme 
survival outcomes (18,19) or tumor cell biology (20) has revealed 
novel genomic classiﬁers that could be validated in independent patient 
cohorts. The ﬁdelity of these classiﬁers in additional large independent 
patient/sample datasets generated in other laboratories remains to be 
conﬁrmed.
While the above gene expression proﬁling studies are mRNA based, 
more recent efforts have used microarray platforms that can proﬁle 
changes in genome wide gene copy number changes (array-compara-
tive genomic hybridization/CGH) and single nucleotide polymorphisms 
(SNP) (21,22). Since DNA is more stable than RNA, these studies may 
be more easily performed using DNA isolated from formalin-ﬁxed 
and parafﬁn embedded archival tumor samples. Array-CGH studies 
